Kelly E. Seaton

机构：International Vaccine Institute, Duke University, St Vincent's Hospital Melbourne, Center for Human Genetics, Duke Medical Center · ORCID：0000-0002-2009-3270

发表论文 115 篇 · 总被引 3902 次 · h-index 29

代表论文

• Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial (2025 · Science Translational Medicine · 被引 44)
• Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial (2024 · The Lancet HIV · 被引 12)
• Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial (2025 · The Lancet HIV · 被引 6)
• Identification of RTS,S/AS01 vaccine–induced humoral biomarkers predictive of protection against controlled human malaria infection (2024 · JCI Insight · 被引 6)
• A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials (2025 · Emerging Microbes & Infections · 被引 5)
• Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV (2025 · BMC Immunology · 被引 3)